Why the study?
Does fondaparinux resolve symptoms in patients with late-onset warfarin-induced purple toe syndrome?
Does fondaparinux resolve symptoms in patients with late-onset warfarin-induced purple toe syndrome?
Fondaparinux can be successfully used as an alternative anticoagulant to resolve late-onset purple toe syndrome caused by warfarin.
May support fondaparinux substitution in warfarin-induced purple toe syndrome; hypothesis-generating case report requiring prospective validation.
Purple toe syndrome is a rarely reported adverse effect of warfarin. In all described cases, the syndrome occurred relatively quickly after initiation of warfarin with little recommendation for treatment in patients needing continued anticoagulation. We encountered a patient who developed purple toes after 1 year of warfarin therapy. The warfarin was stopped, and fondaparinux was substituted with prompt resolution of all his symptoms. This is the first case describing late onset purple toe syndrome with warfarin with successful substitution with fondaparinux.
No takes yet. Share an insight, caveat, or question.
Rindone et al. (2010) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: